KAZIA THERAPEUTICS LTD
KZIANext catalyst
PAXALISIB
Primary Central Nervous System Lymphoma
Get an email about KZIA's next catalysts
Track KAZIA THERAPEUTICS (KZIA) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
No other upcoming event in our data.
1 upcoming, 1 past
PAXALISIB Phase 2 Est. Readout
Estimated primary completion for PAXALISIB trial (NCT04906096) in Primary Central Nervous System Lymphoma. Topline data typically follows completion by weeks to months.
SourceHow KZIA's past catalysts played out
Market Overview
Stock performance and key metrics
PAXALISIB
Primary Central Nervous System Lymphoma
Lomustine
Glioblastoma
Opdualag
Childhood Cancer
Temozolomide capsule
Malignant Primary Gliomas
Adagrasib
CDK Gene Mutation
PI3K Inhibitor paxalisib
CDK Gene Mutation
Irinotecan (drug)
Childhood Cancer
Paxalisib (GDC-0084)
Glioblastoma, Adult
Entrectinib
CDK Gene Mutation
Abemaciclib
CDK Gene Mutation
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
PAXALISIB | Phase 3 | Primary Central Nervous System Lymphoma | - | - |
Lomustine | Phase 3 | Glioblastoma | - | - |
Opdualag | Phase 2 | Childhood Cancer | - | - |
Temozolomide capsule | Phase 2 | Malignant Primary Gliomas | - | - |
Adagrasib | Phase 2 | CDK Gene Mutation | - | - |
PI3K Inhibitor paxalisib | Phase 2 | CDK Gene Mutation | - | - |
Irinotecan (drug) | Phase 2 | Childhood Cancer | - | - |
Paxalisib (GDC-0084) | Phase 2 | Glioblastoma, Adult | - | - |
Entrectinib | Phase 2 | CDK Gene Mutation | - | - |
Abemaciclib | Phase 2 | CDK Gene Mutation | - | - |
Frequently asked questions
What is in KAZIA THERAPEUTICS LTD's drug pipeline?β
CatalystAlert tracks 10 drug candidates in KAZIA THERAPEUTICS LTD's (KZIA) pipeline across Phase 3, Phase 2. Its lead program is PAXALISIB (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is KAZIA THERAPEUTICS LTD's next FDA catalyst?β
KAZIA THERAPEUTICS LTD's (KZIA) next tracked catalyst is a Phase 2 readout expected December 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track KZIA biotech catalysts?β
Add KZIA to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow KAZIA THERAPEUTICS LTD's live catalyst calendar, drug pipeline and clinical-trial timeline on this page β sourced from ClinicalTrials.gov, FDA and SEC filings.
